JP2022502380A5 - - Google Patents

Info

Publication number
JP2022502380A5
JP2022502380A5 JP2021516643A JP2021516643A JP2022502380A5 JP 2022502380 A5 JP2022502380 A5 JP 2022502380A5 JP 2021516643 A JP2021516643 A JP 2021516643A JP 2021516643 A JP2021516643 A JP 2021516643A JP 2022502380 A5 JP2022502380 A5 JP 2022502380A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
antigen
antibody
binding fragment
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2021516643A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022502380A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/052558 external-priority patent/WO2020068723A1/en
Publication of JP2022502380A publication Critical patent/JP2022502380A/ja
Publication of JP2022502380A5 publication Critical patent/JP2022502380A5/ja
Withdrawn legal-status Critical Current

Links

JP2021516643A 2018-09-24 2019-09-24 抗cd154抗体の安全な投与を提供する方法 Withdrawn JP2022502380A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862735529P 2018-09-24 2018-09-24
US62/735,529 2018-09-24
US201962826131P 2019-03-29 2019-03-29
US62/826,131 2019-03-29
PCT/US2019/052558 WO2020068723A1 (en) 2018-09-24 2019-09-24 Method of providing safe administration of an anti-cd154 antibody

Publications (2)

Publication Number Publication Date
JP2022502380A JP2022502380A (ja) 2022-01-11
JP2022502380A5 true JP2022502380A5 (https=) 2022-10-03

Family

ID=69950835

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021516643A Withdrawn JP2022502380A (ja) 2018-09-24 2019-09-24 抗cd154抗体の安全な投与を提供する方法

Country Status (6)

Country Link
US (1) US20210317220A1 (https=)
EP (1) EP3856246A4 (https=)
JP (1) JP2022502380A (https=)
CN (1) CN112770774A (https=)
AU (1) AU2019347730A1 (https=)
WO (1) WO2020068723A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2022016218A (es) * 2020-07-08 2023-03-31 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-ctla-4.

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2682292A1 (en) * 2007-03-30 2008-10-09 Medimmune, Llc Aqueous formulation comprising an anti-human interferon alpha antibody
GB0718684D0 (en) * 2007-09-24 2007-10-31 Roche Products Ltd Treatment method
US9028826B2 (en) * 2011-04-04 2015-05-12 The Trustees Of Dartmouth College Methods of immune therapy with anti-CD154 antibodies having impaired FcR binding and/or complement binding properties
EP3753567A1 (en) * 2011-10-11 2020-12-23 Viela Bio, Inc. Cd40l-specific tn3-derived scaffolds and methods of use thereof
GB201501613D0 (en) * 2015-01-30 2015-03-18 Ucb Biopharma Sprl Treatment of autoimmune disorders with CD154 antibodies
CR20180097A (es) * 2015-07-14 2018-05-25 Immunext Inc Anticuerpo anti-cd154 con caracteristicas de unión, funcionalidad y seguridad mejoradas y uso en inmunoterapia humana
UA123398C2 (uk) * 2015-08-05 2021-03-31 Янссен Байотек, Інк. Виділене антагоністичне антитіло, яке специфічно зв'язує cd154, та фармацевтична композиція, яка його містить

Similar Documents

Publication Publication Date Title
JP2023548858A5 (https=)
US20240417455A1 (en) Treatment for rheumatoid arthritis
CA2146647C (en) Treatment of autoimmune and inflammatory disorders
AU2011210773B2 (en) Methods of treating diabetes with Dll4 antagonists
JP2013542194A5 (https=)
EP3360896B1 (en) Antibody to hepatitis b surface antigen and use thereof
JP2023538369A5 (https=)
JP2024531151A5 (https=)
RU2016133463A (ru) Гуманизированные антитела с повышенной стабильностью
KR20170020423A (ko) 항-hsv 항체의 국소 적용
JP2024527607A5 (https=)
JP2024516698A5 (https=)
JP2024540226A5 (https=)
IL275884B1 (en) Human antibodies to influenza hemagglutinin
JP2023502398A5 (https=)
JP2022502380A5 (https=)
CN118434759A (zh) 用抗-pd-l1/il-10融合蛋白治疗疾病的方法
JP2022527542A5 (https=)
JP2022534494A5 (https=)
JP2024517087A5 (https=)
Guillevin Clinical trials on systemic necrotizing vasculitides
NZ777838B2 (en) Anti-cd38 antibodies and pharmaceutical compositions thereof for the treatment of autoantibody-mediated autoimmune disease
Hermida Use of biologic agents in cutaneous emergencies
NZ777838A (en) Anti-cd38 antibodies and pharmaceutical compositions thereof for the treatment of autoantibody-mediated autoimmune disease
Boogaerts The use of intravenous immunoglobulins in bone marrow transplantation